Table 1.
Baseline clinical and biochemical features in patients with Paget’s disease of bone (PDB) as a whole or separately as patients with polyostotic (PO-PDB) and monostotic (MO-PDB) disease
| PDB (n = 47) | PO-PDB (n = 22) | MO-PDB (n = 25) | Ref. range | |
|---|---|---|---|---|
| Sex (M / F) | 24/23 | 11/11 | 13/12 | |
| Age (years) | 72.5 ± 8.9 | 71.5 ± 10.5 | 73.4 ± 7.4 | |
| BMI (kg/m2) | 27.2 ± 5.5 | 26.1 ± 5.8 | 28.1 ± 5.3 | 18.5–24.9 |
| Time since PDB diagnosis (years) | 6.9 ± 8.6 | 6.4 ± 9.3 | 7.3 ± 8.2 | |
| ALP (UI/l) | 449.0 ± 682.9 | 608.8 ± 908.4 | 272.4 ± 175.7 | 50–150 |
| BAP (mcg/l) | 53.3 ± 33.1 | 65.5 ± 34.9a | 41.7 ± 27.3 | < 21 |
| Serum total calcium (mmol/l) | 2.3 ± 0.1 | 2.3 ± 0.2 | 2.3 ± 0.1 | 2.2–2.6 |
| Serum ionized calcium (mmol/l) | 1.2 ± 0.1 | 1.1 ± 0.1 | 1.2 ± 0.1 | 1.1–1.3 |
| Urinary calcium (mmol/die) | 2.7 ± 1.5 | 2.9 ± 0.8 | 2.6 ± 1.8 | 2.5–7.5 |
| Parathormone (pmol/l) | 4.85 ± 2.90 | 4.33 ± 1.47 | 5.33 ± 3.79 | 1.05–6.90 |
| 25(OH) vitamin D (nmol/l) | 54.7 ± 25.5 | 60.9 ± 24.5 | 48.7 ± 25.7 | 75–125 |
| Serum creatinine (µmol/l) | 75.4 ± 16.0 | 76.5 ± 19.5 | 74.5 ± 12.7 | 44–106 |
| Creatinine clearance (ml/s) | 1.3 ± 0.4 | 1.2 ± 0.4 | 1.4 ± 0.2 | 1.2–2.0 |
| Bone pain at involved pagetic site(s) | 16 (34) | 9 (41) | 7 (28) | |
| Pagetic fracturesb | 5 (11) | 3 (14) | 2 (8) | |
| Deafness | 1 (2) | 1 (5) | 0 (0) | |
| Bone deformities | 3 (6) | 2 (9) | 1 (4) | |
| Osteoarthritis | 18 (38) | 10 (45) | 8 (32) |
Data are presented as mean ± standard deviation or n (percentage). Statistical analysis is performed by Mann–Whitney test and Pearson’s Χ2
BMI body mass index, ALP alkaline phosphatase, BAP bone alkaline phosphatase
ap < 0.05 vs MO-PDB
bSpecifically, pagetic fractures occurred at vertebral sites (n = 4) and at the hip (n = 1)